Related Experiment Videos

Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway

Fei Chen1, Zhuo Zhang, Jacquelyn Bower

  • 1Health Effects Laboratory Division, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, USA. lfd3@cdc.gov

Insights

Arsenite, a carcinogen, halts cell cycle progression at G(2)/M by degrading Cdc25C via the ubiquitin-proteasome pathway. This implicates cell cycle regulation in arsenite

Area of Science:

  • Toxicology
  • Cell Biology
  • Molecular Biology

Background:

  • Arsenite is a known human carcinogen.
  • Carcinogenesis can occur via genotoxic or epigenetic mechanisms.
  • Cell cycle regulation is crucial for preventing uncontrolled cell proliferation.

Purpose of the Study:

  • To investigate the effects of arsenite on cell cycle regulation.
  • To elucidate the molecular mechanisms underlying arsenite-induced cell cycle arrest.
  • To determine the role of Cdc25C degradation in arsenite's carcinogenic pathway.

Main Methods:

  • Cell proliferation and viability assays.
  • Cell cycle analysis using flow cytometry.
  • Western blotting to assess cell cycle regulatory proteins.
  • Ubiquitination assays and site-directed mutagenesis of Cdc25C.

Main Results:

  • Arsenite treatment suppressed cell proliferation and reduced cell viability.
  • Arsenite induced cell cycle arrest at the G(2)/M phase.
  • Arsenite promoted the degradation of Cdc25C through the ubiquitin-proteasome pathway.
  • Mutating the KEN box of Cdc25C or using a peptide competitor partially inhibited arsenite-induced ubiquitination.

Conclusions:

  • Regulated ubiquitination of Cdc25C is involved in arsenite-induced proteolytic down-regulation.
  • Cdc25C activity modulation in G(2)/M phase is a key mechanism in arsenite's effects.
  • This study suggests a link between cell cycle disruption and arsenite's carcinogenic properties.

Related Concept Videos